There are 2137 resources available
1284P - MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
Presenter: Enriqueta Felip
Session: E-Poster Display
Resources:
Abstract
1285P - Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
Presenter: Johan Vansteenkiste
Session: E-Poster Display
Resources:
Abstract
1286P - Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC
Presenter: Santiago Viteri
Session: E-Poster Display
Resources:
Abstract
1287P - Efficacy and safety of entrectinib in locally advanced/metastatic <italic>ROS1</italic> fusion-positive NSCLC: An updated integrated analysis
Presenter: Matthew G Krebs
Session: E-Poster Display
Resources:
Abstract
1288P - Efficacy of entrectinib in patients with <italic>NTRK</italic> or <italic>ROS1</italic> fusion-positive NSCLC with CNS metastases at baseline
Presenter: Rafal Dziadziuszko
Session: E-Poster Display
Resources:
Abstract
1289P - Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
Presenter: Alexander Drilon
Session: E-Poster Display
Resources:
Abstract
1290P - Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion + non-small cell lung cancer (NSCLC)
Presenter: Oliver Gautschi
Session: E-Poster Display
Resources:
Abstract
1291P - Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI)
Presenter: Caroline McCoach
Session: E-Poster Display
Resources:
Abstract
1292P - Exploratory patient-reported outcomes (PROs) among patients with RET-fusion non-small cell lung cancer (NSCLC) in LIBRETTO-001: A phase I/II trial of selpercatinib
Presenter: Anna Minchom
Session: E-Poster Display
Resources:
Abstract
1293P - IMpower150: Updated efficacy analysis in patients with EGFR mutations
Presenter: Martin Reck
Session: E-Poster Display
Resources:
Abstract